BACKGROUND: Dyslipidemia and obesity have been observed in persons with severe anxiety or depression, and in tricyclic antidepressant (TCA) users. This likely contributes to the higher risk of cardiovascular disease (CVD) in anxiety and depressive disorders. We aimed to elucidate whether biological stress systems or lifestyle factors underlie these associations. If so, they may be useful targets for CVD prevention and intervention. METHODS: Within 2850 Netherlands Study of Depression and Anxiety (NESDA) participants, we evaluated the explaining impact of biological stress systems (i.e., the hypothalamic-pituitary-adrenal [HPA] axis, autonomic nervous system [ANS] and inflammation) and lifestyle factors (i.e., tobacco and alcohol use, and physical activity) on adverse associations of anxiety and depression severity and TCA use with high and low-density lipoprotein cholesterol, triglycerides, body mass index and waist circumference. Through linear regression analyses, percentual change (%Δ) in β was determined and considered significant when %Δ>10. RESULTS: The inflammatory marker C-reactive protein had the most consistent impact (explaining 14-53% of the associations of anxiety and depression severity and TCA use with lipid and obesity levels), followed by tobacco use (explaining 34-43% of the associations with lipids). The ANS mediated all associations with TCA use (explaining 32-61%). The HPA axis measures did not explain any of the associations. CONCLUSIONS: Increased dyslipidemia and (abdominal) obesity risk in patients with more severe anxiety disorders and depression may be partly explained by chronic low-grade inflammation and smoking. TCAs may increase metabolic risk through enhanced sympathetic and decreased parasympathetic ANS activity. That the HPA axis had no impact in our sample may reflect the possibility that the HPA axis only plays a role in acute stress situations rather than under basal conditions.
BACKGROUND:Dyslipidemia and obesity have been observed in persons with severe anxiety or depression, and in tricyclic antidepressant (TCA) users. This likely contributes to the higher risk of cardiovascular disease (CVD) in anxiety and depressive disorders. We aimed to elucidate whether biological stress systems or lifestyle factors underlie these associations. If so, they may be useful targets for CVD prevention and intervention. METHODS: Within 2850 Netherlands Study of Depression and Anxiety (NESDA) participants, we evaluated the explaining impact of biological stress systems (i.e., the hypothalamic-pituitary-adrenal [HPA] axis, autonomic nervous system [ANS] and inflammation) and lifestyle factors (i.e., tobacco and alcohol use, and physical activity) on adverse associations of anxiety and depression severity and TCA use with high and low-density lipoprotein cholesterol, triglycerides, body mass index and waist circumference. Through linear regression analyses, percentual change (%Δ) in β was determined and considered significant when %Δ>10. RESULTS: The inflammatory marker C-reactive protein had the most consistent impact (explaining 14-53% of the associations of anxiety and depression severity and TCA use with lipid and obesity levels), followed by tobacco use (explaining 34-43% of the associations with lipids). The ANS mediated all associations with TCA use (explaining 32-61%). The HPA axis measures did not explain any of the associations. CONCLUSIONS: Increased dyslipidemia and (abdominal) obesity risk in patients with more severe anxiety disorders and depression may be partly explained by chronic low-grade inflammation and smoking. TCAs may increase metabolic risk through enhanced sympathetic and decreased parasympathetic ANS activity. That the HPA axis had no impact in our sample may reflect the possibility that the HPA axis only plays a role in acute stress situations rather than under basal conditions.
Authors: Chadi A Calarge; James A Mills; Kathleen F Janz; Trudy L Burns; William H Coryell; Babette S Zemel Journal: Pediatrics Date: 2017-06-16 Impact factor: 7.124
Authors: Maria Carmen Viana; Carmen C W Lim; Flavia Garcia Pereira; Sergio Aguilar-Gaxiola; Jordi Alonso; Ronny Bruffaerts; Peter de Jonge; Jose Miguel Caldas-de-Almeida; Siobhan O'Neill; Dan J Stein; Ali Al-Hamzawi; Corina Benjet; Graça Cardoso; Silvia Florescu; Giovanni de Girolamo; Josep Maria Haro; Chiyi Hu; Viviane Kovess-Masfety; Daphna Levinson; Marina Piazza; José Posada-Villa; Daniel Rabczenko; Ronald C Kessler; Kate M Scott Journal: J Pain Date: 2017-10-12 Impact factor: 5.820
Authors: Maria Elizabeth de Sousa Rodrigues; Mandakh Bekhbat; Madelyn C Houser; Jianjun Chang; Douglas I Walker; Dean P Jones; Claudia M P Oller do Nascimento; Christopher J Barnum; Malú G Tansey Journal: Brain Behav Immun Date: 2016-09-02 Impact factor: 7.217
Authors: Claudia A Grillo; Petra Mulder; Victoria A Macht; Kris F Kaigler; Steven P Wilson; Marlene A Wilson; Lawrence P Reagan Journal: Physiol Behav Date: 2014-02-08
Authors: Paul A Dennis; Christi S Ulmer; Patrick S Calhoun; Andrew Sherwood; Lana L Watkins; Michelle F Dennis; Jean C Beckham Journal: J Psychosom Res Date: 2014-05-14 Impact factor: 3.006
Authors: William H Coryell; Brandon D Butcher; Trudy L Burns; Lilian N Dindo; Janet A Schlechte; Chadi A Calarge Journal: J Clin Psychiatry Date: 2016-01 Impact factor: 4.384
Authors: Kasra Moazzami; Matthew T Wittbrodt; Bruno B Lima; Oleksiy Levantsevych; Belal Kaseer; Afif Martini; Ammer Haffar; Jonathon A Nye; Arshed A Quyyumi; Amit Shah; Viola Vaccarino; J Douglas Bremner Journal: Psychosom Med Date: 2020-04 Impact factor: 3.864